Reposting this here since it has nothing to do with the volume thread:
Enter Andrea Leone Bay and the RLS connection, When Andrea was affiliated with MNKD she was involved with pain inhalation studies with Torrey Pines, there are some interesting findings from those studies I remember seeing in relation to the quick relief that resulted from inhaled technosphere meds. Years ago, at one of the annual shareholder meetings in Valencia Al mentioned how badly his wife suffered from migraines and he believed that technosphere would eventually be able to aid in the treatment of migraines and other areas of pain management in a much more efficient manner.
Thus, patents.justia.com/patent/9610351
I imagine there is some deal/prior agreement with Andrea/RLS/MNKD with a prior agreement relative to the company's mission statement "your drug, our delivery" IMO.
Read more:
mnkd.proboards.com/thread/8702/volume-tree?page=53#ixzz4wetrz7W3Adding: (pg38 from following:
www.ddtwc.com/pdf/Abstract-Book-2016.pdfSL-105
Track: Pharmaceutical Research & Development
DEVELOPMENT OF HEAT-STABLE OXYTOCIN FORMULATIONS FOR ORAL INHALATION
K. Fabio, K. Curley, J. Guarneri, M. Grant, A. Leone-Bay, R. Offord and K. Kraft
Mannkind corporation, Danbury, CT, USA; E-mail: kfabio@mannkindcorp.com
Drug delivery by oral inhalation has long been the standard of care for pulmonary diseases like
asthma. Recently, however, an inhaled formulation of insulin (Afrezza® inhalation powder;
MannKind Corporation) was approved by the FDA for the treatment of diabetes, opening drug
delivery by oral inhalation for use in other systemic diseases. Herein, we present work toward
developing an orally inhaled oxytocin dry powder formulation. Oxytocin, a peptide hormone, is the
first choice among uterotonic agents to prevent post-partum hemorrhage (IV/IM 10 IU). However,
access to oxytocin therapy in developing countries, is limited by the requirements for injected delivery and cold chain
storage. These limitations result in a higher maternal death rate from post-partum hemorrhage in these countries.
Therefore, prototype inhalable oxytocin dry powders were prepared, focusing on excipients that promote oxytocin
stability and engineered particles suitable for patient self-delivery by oral inhalation. These powders were evaluated for
chemical and physical stability at accelerated conditions, and for pulmonary delivery performance through an
inexpensive and robust breath powered Dreamboat™ inhaler. Critical attributes required for powder performance were
identified. In vivo systemic drug exposure following pulmonary insufflation was confirmed in rats.
